A randomised, double-blind, placebo-controlled, multiple oral dose, dose escalation trial, investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of NNC 55-0414 [tifenazoxide] in patients with type 2 diabetes
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Tifenazoxide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 10 Nov 2009 Actual end date (1 May 2001) added as reported by ClinicalTrials.gov.
- 10 Nov 2009 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 05 Dec 2006 New trial record.